BLACK HILLS REGIONAL EYE INSTITUTE

Clinical Research Trials

Principal Investigators Include: Stephen Khachikian, MD & Adam Jorgensen, MD

For more information, please call Lizza Teller at 605-719-3204

Company & Study name	Study Rationale	Study Candidates & Duration	Current Enrollment
Glaucoma **ALLERGAN** **PI: Jorgensen** **SUBI: Khachikian**	A Phase 3b, Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension	Patients with Glaucoma Bimatoprost SR refers to the biodegradable, sustained-release, preservative-free bimatoprost implant 4-years	Open
Sjögren's **LEXITAS** **SYL1001_V** **PI: Khachikian** **SUBI: Schirber Bergman**	Tivanisiran for Dry Eye in Subjects with Sjögren's Syndrome (SYL1001_V) Phase 2 Multicenter, randomized (1:1) study with a 14-day, single-masked, Run-In vehicle treatment phase followed by an 85-day, double-masked, active and vehicle-controlled treatment phase in approximately 200 subjects with dry eye associated with Sjogren's Syndrome	Patients with Sjogren's Drops once a day for 2 weeks. 3 months (5 visits)	Open
Dry eye **SYLENTIS** **SYL1001_VI** **PI: Khachikian** **SUBI: Schirber Scarborough**	Safety Study of Tivanisiran to Treat Dry Eye (SYL1001_VI): FYDES Study. Multicenter, double-masked, parallel, vehicle-controlled, randomized (2:1, 1.125% tivanisiran sodium ophthalmic solution: vehicle) study in approximately 300 subjects with mild to severe dry eye disease (DED).	Patients with Dry Eye Disease Drops once a day for a year. 1 year (7 in office visits, 5 phone visits)	Open
	Contact Lizza Teller at 605-719-3204		